Agios Pharmaceuticals Stock (NASDAQ:AGIO)
Previous Close
$28.44
52W Range
$26.66 - $62.58
50D Avg
$32.77
200D Avg
$41.90
Market Cap
$1.59B
Avg Vol (3M)
$725.58K
Beta
0.83
Div Yield
-
AGIO Company Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ARVN | Arvinas, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| BMRN | BioMarin Pharmaceutical Inc. |
| BPMC | Blueprint Medicines Corporation |
| ANAB | AnaptysBio, Inc. |
| IDYA | IDEAYA Biosciences, Inc. |
| MRSN | Mersana Therapeutics, Inc. |
| KALV | KalVista Pharmaceuticals, Inc. |
| MREO | Mereo BioPharma Group plc |
| FIXX | Q32 Bio Inc. |
| MGTX | MeiraGTx Holdings plc |
| RVMD | Revolution Medicines, Inc. Warrant |
| BDTX | Black Diamond Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| KROS | Keros Therapeutics, Inc. |